NCT06605703CompletedPhase 4
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
The Comparative Effectiveness of Step-down Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide: A Randomized Controlled Trial (GLP1 Transition Trial)
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
The study compares the effectiveness of treatment options for weight management after discontinuing semaglutide and tirzepatide. The primary outcome is absolute and percentage weight change at 12-weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 226 (actual)
- First submitted
- 18 Sept 2024
- Start date
- 18 Sept 2024
- Primary completion date
- 5 Feb 2026
- Lead sponsor
- WW International Inc
- Diseases
- Obesity
- NCT number
- NCT06605703
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 226
- From 18 Sept 2024 to the primary completion date, 5 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous surgical obesity treatment
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, antiepileptic drugs
- Use of antipsychotic medications or opiod analgesics
- Current or previous history of anorexia or bulimia nervosa
- Current SSRI, SNRI, mood stabilizer, amphetamine, or corticosteroid use
- Current use of Monoamine Oxidase Inhibitors (MAOIs)
Other illness
- Diabetes
- History of seizures or epilepsy
- History of glaucoma
- Uncontrolled hypertension
- Acute hepatitis or liver failure
- Current diagnosis of Cushing's disease or syndrome
- Known hypersensitivity to bupropion, naltrexone, or metformin
Lab values
- Severe renal impairment and/or Chronic kidney disease stage III or GFR \<60
Other
- BMI \<22 kg/m2
- Currently pregnant or intending to become pregnant during the study
- Breastfeeding
- Current opioid use or in acute opioid withdrawal
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Engagement with vomiting or laxative use within the last 28 days with the aim of controlling their shape or weight
- Current diagnosis of hyper or hypothyroidism or current use of thyroid replacement medicine
- Current use of beta blockers
- Current use of depo shot (medroxyprogesterone acetate) for birth control
- Any other reason rendering a participant unsuitable for trial participation, as determined by a clinician or study investigator
Who the study is looking for
- 18 years or older
- Previous hx of BMI of \>30 or BMI of \>27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease)
- Currently taking Wegovy, Ozempic, Mounjaro or Zepbound and have been for at least 6 months
- At least 15% body weight loss since taking Wegovy, Ozempic, Mounjaro, or Zepbound
- Willing to stop taking their GLP-1 medication or is discontinuing due to circumstances such as access, cost, coverage, choice, or any other reason
- Ability to provide informed consent prior to any trial-related activities
- Able to read and write in English
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| WW International, Inc Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.